Dyslipidemia

Hypercholesterolemia is an important, modifiable cardiovascular risk factor. Besides the classical risk factors like LDL-C and apoB, other lipid risk factors like Lp(a), fasting and non-fasting triglycerides and HDL-C are important treatment targets for which different novel interventions are being developed. Modification of these risk factors represents an unmet clinical need and may help to reduce the well-known residual cardiovascular risk in clinical practice.

Recruiting a vast number of suitable dyslipidemia patients within a limited time frame at affordable costs, while maintaining high data quality and integrity can be a challenge. To overcome these hurdles, we have a dedicated expert team that is ready to provide you with the perfect tailor-made solution for your Dyslipidemia clinical trial.

Meet our scientific leaders for Dislipidemia clinical trials

Prof. Dr. Manuel Castro Cabezas is an internationally recognized expert in the field of lipids and associated diseases. He works as Scientific Officer for Julius Clinical and as a Senior consultant for internal medicine, endocrinology, and vascular medicine at the Franciscus Gasthuis Rotterdam. Prof. Castro Cabezas has participated in many clinical trials as PI and as initiator, in the fields of lipid management, diabetes and obesity.

Meet our scientific leaders for Dislipidemia clinical trials

Prof. Dr. Marco Alings is s a practicing cardiologist/electrophysiologist and Director of the cardiology training program at the Amphia Ziekenhuis, Breda, the Netherlands. Prof. Alings is a clinical trialist with a special interest in arrhythmias and stroke prevention, and has served as national coordinator for many large international multicenter studies.

Our Cardio Clinical network is based on solid and long collaborations with scientific experts in the field of cardiovascular diseases. The network consists of cardiologists and researchers from 833 sites in 20 countries, focusing on the development of novel therapies for Cardiovascular Diseases including lipid lowering cardiovascular intervention trials, stroke prevention and heart failure.

Read more

A selection of our Dyslipidemia clinical trials

 

CLEAR Outcomes

Phase III, Global

1667 Patients | 12 Countries | 224 Sites

Cardiovascular events in patients who are statin intolerant.

SPIRE I

Phase III, Global

4300 Patients | 26 Countries | 481 Sites

Reducing occurrence of major cardiovascular events in high risk subjects.

 

 

SPIRE II

Phase III, Global

2300 Patients | 26 Countries | 451 Sites

Reducing occurrence of major cardiovascular events in high risk subjects.


Our expert team for Dyslipidemia

Our expert team has many years of experience in conducting clinical trials in the field of Dyslipidemia and will provide you with a tailor-made solution that suits your needs.

Rick grobbee
Wiebe-Buitenwerf
Marcel bootsma
Marco alings
Elizabeth liano callahan

Dyslipidemia resources

Explore our Dyslipidemia case studies.

Download

"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Request for proposal

"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
This field is for validation purposes and should be left unchanged.

Share

Twitter Facebook LinkedIn